Ultrasound improved immune adjuvant delivery to induce DC maturation and T cell activation

J Control Release. 2022 Sep:349:18-31. doi: 10.1016/j.jconrel.2022.06.054. Epub 2022 Jul 4.

Abstract

Tumor immunotherapy has emerged as a promising approach to tumor treatment. Currently, immune adjuvant-based therapeutic modalities are rarely curative in solid tumors owing to challenges including the low permeability and extremely poor water solubility of these adjuvants, limiting their ability to effectively promote dendritic cell (DC) maturation. Herein, we employed ultrasound-mediated cavitation (UMC) to promote the delivery of Toll-like receptor agonist (R837)-loaded pH-responsive liposomes (PEOz-Lip@R837) to tumors. The tumor-associated antigens (TAAs) produced by UMC treatment exhibited vaccinal activity, particularly in the presence of immune adjuvants, together promoting the maturation of DC and inducing cytokine production. Importantly, UMC can down-regulate immune checkpoint molecules, like Cd274, Foxp3 and Ctla4, synergistically stimulating the activation and proliferation of T cells in the body to facilitate tumor treatment. This UMC-enhanced PEOz-Lip@R837 approach was able to induce a robust antitumor immune response capable of arresting primary and distant tumor growth, while also developing immunological memory, protecting against tumor rechallenge following initial tumor clearance. Overall, these results highlight a promising UMC- and pH-sensitive immune adjuvant delivery-based treatment for tumors with the potential for clinical application.

Keywords: Drug release; Immunotherapy; Pancreatic cancer; Ultrasound-mediated cavitation; pH-sensitive.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • CTLA-4 Antigen
  • Cytokines
  • Dendritic Cells* / cytology
  • Forkhead Transcription Factors
  • Humans
  • Imiquimod / pharmacology
  • Immune Checkpoint Proteins
  • Immunotherapy / methods
  • Liposomes*
  • Lymphocyte Activation
  • Neoplasms* / therapy
  • T-Lymphocytes* / cytology
  • Toll-Like Receptors

Substances

  • Adjuvants, Immunologic
  • CTLA-4 Antigen
  • Cytokines
  • Forkhead Transcription Factors
  • Immune Checkpoint Proteins
  • Liposomes
  • Toll-Like Receptors
  • Imiquimod